3B Pharmaceuticals GmbH products

3B Pharmaceuticals have built a drug discovery platform extending from hit identification to early clinical development. Several drug candidates developed through our platform already have been successfully administered to humans.

Discovery and preclinical development of peptide drug candidates have been 3BP’s core competencies since the company’s inception.

Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical areas for diagnosis and/or therapy. Targeted radiopharmaceuticals bind to specific structures such as proteins or cells within the body and thus accumulate in particular places, such as e.g. tumor lesions in a cancer patient.

3B Pharmaceuticals (3BP) is a leading developer of targeted molecular radiopharmaceuticals focusing on cancer indications with high medical need. The focus of our drug development programs is a theragnostic approach using diagnostic imaging to identify patients who are likely responders to radiopharmaceutical therapy. 3BP has built a unique technology platform for the efficient discovery and validation of cancer radiopharmaceuticals.